NCT03748641 2026-04-13MAGNITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting765 enrolled 16 charts 2 FDA
NCT04497844 2026-04-13AMPLITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting696 enrolled 15 charts 2 FDA
NCT03732820 2026-01-29Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZenecaPhase 3 Active not recruiting895 enrolled 19 charts 2 FDA